| Literature DB >> 28644039 |
Katrina Gwinn1, Karen K David1, Christine Swanson-Fischer1, Roger Albin2, Coryse St Hillaire-Clarke3, Beth-Anne Sieber1, Codrin Lungu1, F DuBois Bowman4, Roy N Alcalay5, Debra Babcock1, Ted M Dawson6, Richard B Dewey7, Tatiana Foroud8, Dwight German9, Xuemei Huang10, Vlad Petyuk11, Judith A Potashkin12, Rachel Saunders-Pullman13, Margaret Sutherland1, David R Walt14, Andrew B West15, Jing Zhang16, Alice Chen-Plotkin17, Clemens R Scherzer18, David E Vaillancourt19, Liana S Rosenthal20.
Abstract
Biomarkers for Parkinson's disease (PD) diagnosis, prognostication and clinical trial cohort selection are an urgent need. While many promising markers have been discovered through the National Institute of Neurological Disorders and Stroke Parkinson's Disease Biomarker Program (PDBP) and other mechanisms, no single PD marker or set of markers are ready for clinical use. Here we discuss the current state of biomarker discovery for platforms relevant to PDBP. We discuss the role of the PDBP in PD biomarker identification and present guidelines to facilitate their development. These guidelines include: harmonizing procedures for biofluid acquisition and clinical assessments, replication of the most promising biomarkers, support and encouragement of publications that report negative findings, longitudinal follow-up of current cohorts including the PDBP, testing of wearable technologies to capture readouts between study visits and development of recently diagnosed (de novo) cohorts to foster identification of the earliest markers of disease onset.Entities:
Keywords: NINDS; PDBP; Parkinson's disease; biomarkers
Mesh：
Substances：
Year: 2017 PMID： 28644039 PMCID： PMC5619098 DOI： 10.2217/bmm-2016-0370
Source DB: PubMed Journal: Biomark Med ISSN： 1752-0363 Impact factor: 2.851